Vertex Pharmaceuticals (VRTX) Fundamental Analysis: Revenue, Earnings & Valuation

4.61 / 10

Netural

Fundamentally, Vertex scores 4.6/10, indicating moderate strength. Profit‑to‑market and cash‑to‑market ratios are favorable, while revenue‑to‑market and current‑asset turnover lag. Asset‑to‑market is slightly negative, and margins are mixed, suggesting a selective, balanced view.

Analysis Checks(6/10)

Revenue-MV

Value-0.92

Score0/3

Weight27.74%

1M Return5.06%

Net cash flow from operating activities per share (YoY growth rate %)

Value845.75

Score0/3

Weight-14.77%

1M Return-3.67%

Inventory turnover ratio

Value1.14

Score2/3

Weight-5.04%

1M Return-1.20%

Gross profit margin (%)

Value86.24

Score0/3

Weight-28.49%

1M Return-7.64%

Profit-MV

Value0.71

Score2/3

Weight33.47%

1M Return6.22%

Current assets turnover ratio

Value1.15

Score1/3

Weight-1.77%

1M Return-0.40%

Fixed assets turnover ratio

Value4.22

Score2/3

Weight-0.29%

1M Return-0.06%

Cost of sales ratio (%)

Value13.79

Score2/3

Weight-18.11%

1M Return-4.69%

Asset-MV

Value-0.55

Score2/3

Weight74.53%

1M Return12.78%

Cash-MV

Value-1.31

Score2/3

Weight32.74%

1M Return6.03%

Is VRTX fundamentally strong?

VRTX scores 4.61/10 on fundamentals and holds a Fair valuation at present. Backed by its 22.54% ROE, 32.94% net margin, 28.83 P/E ratio, 6.11 P/B ratio, and 843.27% earnings growth, these metrics solidify its Netural investment rating.